Disc Medicine, Inc. $IRON Shares Sold by Atlas Venture Life Science Advisors LLC

Atlas Venture Life Science Advisors LLC cut its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 29.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,513,875 shares of the company’s stock after selling 628,742 shares during the quarter. Disc Medicine makes up about 13.9% of Atlas Venture Life Science Advisors LLC’s investment portfolio, making the stock its 4th largest position. Atlas Venture Life Science Advisors LLC’s holdings in Disc Medicine were worth $120,217,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in Disc Medicine by 823.8% in the fourth quarter. Renaissance Technologies LLC now owns 62,820 shares of the company’s stock valued at $4,989,000 after acquiring an additional 56,020 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Disc Medicine in the fourth quarter valued at approximately $298,000. Campbell & CO Investment Adviser LLC lifted its stake in Disc Medicine by 228.9% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 17,399 shares of the company’s stock valued at $1,382,000 after acquiring an additional 12,109 shares during the last quarter. Bank of Montreal Can lifted its stake in Disc Medicine by 39.6% in the fourth quarter. Bank of Montreal Can now owns 24,826 shares of the company’s stock valued at $1,971,000 after acquiring an additional 7,041 shares during the last quarter. Finally, Loomis Sayles & Co. L P acquired a new stake in Disc Medicine in the fourth quarter valued at approximately $22,426,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research note on Wednesday. Cantor Fitzgerald reduced their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wells Fargo & Company boosted their price objective on shares of Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Finally, Truist Financial reduced their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.30.

Disc Medicine Trading Down 0.1%

Shares of IRON stock opened at $67.99 on Friday. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The firm’s fifty day simple moving average is $68.16 and its 200 day simple moving average is $72.57. The firm has a market capitalization of $2.59 billion, a P/E ratio of -10.27 and a beta of 0.93. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, sell-side analysts predict that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Jean M. Franchi sold 6,257 shares of the business’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the transaction, the chief financial officer owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. The trade was a 8.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William Jacob Savage sold 5,731 shares of the business’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $66.38, for a total transaction of $380,423.78. Following the transaction, the insider directly owned 79,480 shares in the company, valued at $5,275,882.40. This trade represents a 6.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,388 shares of company stock worth $841,258 in the last ninety days. 3.76% of the stock is currently owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.